Methods and related aspects for detecting necrotizing enterocolitis (NEC)
Measuring TLR4 levels in biological samples allows for early and accurate NEC diagnosis and treatment, addressing the inadequacies of current diagnostic methods and treatments by targeting TLR4 pathways to manage NEC effectively.
Patent Information
- Application Number
- PCT/US2026/026821
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Current diagnostic tests for necrotizing enterocolitis (NEC) in premature infants are inadequate, leading to high mortality rates due to the lack of specific biomarkers, and existing treatments are largely reactive rather than proactive.
Measuring circulating Toll-like receptor 4 (TLR4) levels in biological samples to diagnose NEC and administer TLR4-targeted therapies, using TLR4 inhibitors to treat the condition, and employing diagnostic kits and systems to detect and manage NEC.
Provides early and accurate diagnosis of NEC stages, enabling timely therapeutic interventions that reduce morbidity and mortality by targeting TLR4 activation pathways, thereby stabilizing the intestinal environment and preventing severe complications.
Smart Images

Figure US2026026821_12112026_PF_FP_ABST
Abstract
Description
Attorney Docket Number 0184.0350-PCT (P18916-02)METHODS AND RELATED ASPECTS FOR DETECTING NECROTIZING ENTEROCOLITIS (NEC)CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application Ser. No. 63 / 800,650, filed May 6, 2025, the disclosure of which is incorporated herein by reference.BACKGROUND
[0002] Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease in premature infants globally and affects up to 10% of premature births, representing 3000-5000 cases annually in the USA. Infants with NEC typically present with findings of abdominal distention, bloody stools, and systemic sepsis, which reflect the acute development of intestinal inflammation and necrosis. Current epidemiological studies have identified prematurity (10 fold), formula feeds (10-20 fold), and a dysbiotic intestinal microbiome rich in lipopolysaccharide (3 fold) as the key risk factors for NEC development. Approximately half of all patients who develop NEC will die, a sobering finding that is attributable in part to the lack of specific diagnostic tests.
[0003] Accordingly, there is a need for additional methods of diagnosing and treating NEC in patients.SUMMARY
[0004] In one aspect, the present disclosure provides a method of detecting or diagnosing necrotizing enterocolitis (NEC) in a subject. The method comprises measuring a level of circulating Toll-like receptor 4 (TLR4) in a biological sample obtained from the subject, and comparing the measured level to a reference level, wherein a level above the reference level is indicative of NEC.
[0005] In another aspect, the present disclosure provides a method for selecting a subject with necrotizing enterocolitis (NEC) for a specific therapeutic intervention. The method comprises measuring a level of circulating Toll-like receptor 4 (TLR4) in a sample from the subject; and administering a TLR4-targeted therapy or an NEC-specific treatment to the subject if the level of TLR4 is above a predetermined threshold.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0006] In another aspect, the present disclosure provides a method of treating necrotizing enterocolitis (NEC) in a subject. The method comprises obtaining a biological sample from a subject suspected of having NEC; detecting a level of circulating Toll-like receptor 4 (TLR4) in the sample; and administering an NEC therapy to the subject if the level of TLR4 is at least 0.5 ng / mL, thereby treating the NEC.
[0007] In another aspect, the present disclosure provides a kit for the diagnosis of necrotizing enterocolitis (NEC) in a premature infant. The kit comprises a reagent for specifically detecting Toll-like receptor 4 (TLR4) in a plasma or stool sample; and instructions for using the reagent to detect NEC or a complication of NEC in the subject based on a measured TLR4 level.
[0008] In another aspect, the present disclosure provides a system for detecting necrotizing enterocolitis (NEC) comprising an assay device configured to measure Toll-like receptor 4 (TLR4) in a biological sample; and a processor and memory containing instructions to compare the measured TLR4 level to a reference range and output a diagnostic result indicating the presence or stage of NEC.BRIEF DESCRIPTION OF THE DRAWINGS
[0009] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate certain embodiments, and together with the written description, serve to explain certain principles of the methods, uses, kits, devices, systems, and related compositions disclosed herein. The description provided herein is better understood when read in conjunction with the accompanying drawings which are included by way of example and not by way of limitation. It will be understood that like reference numerals identify like components throughout the drawings, unless the context indicates otherwise. It will also be understood that some or all of the figures may be schematic representations for purposes of illustration and do not necessarily depict the actual relative sizes or locations of the elements shown.
[0010] FIG. 1A is a flowchart that shows an exemplary method detecting or diagnosing necrotizing enterocolitis (NEC) in a subject in accordance with an embodiment.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0011] FIG. 1 B is a flowchart that shows an exemplary method for selecting a subject with necrotizing enterocolitis (NEC) for a specific therapeutic intervention in accordance with an embodiment.
[0012] FIG. 1C is a flowchart that shows an exemplary method of treating necrotizing enterocolitis (NEC) in a subject in accordance with an embodiment.
[0013] FIG. 2 is a schematic diagram of an exemplary system suitable for use with certain aspects disclosed herein.
[0014] FIGS. 3A-3K show that TLR4 activation on the intestinal epithelium is required for NEC development. FIGS. 3A-3F show gross and H&E images of the ileum of wild-type or TLR4AIECmice that are either breastfed controls or induced to develop NEC; FIGS. 3G-3I are images of ilea stained for the ROS marker DHE; FIGS.3J and 3K are data plots that show disease severity as measured by Tnf expression and NEC injury score. ***p<0.001, each dot separate mouse; 3 separate expts. bar= 50um.
[0015] FIG. 4 is a data plot showing TLR4 levels detected in the stool of mice with NEC.
[0016] FIG. 5 is a data plot showing that plasma TLR4 levels rise prior to the onset of full-blown NEC in mice.
[0017] FIG. 6 is a data plot showing that plasma TLR4 levels are higher in early (medical NEC) than in late (surgical NEC).
[0018] FIG. 7 is a data plot showing that TLR4 levels are detected in the stool of mice with NEC.
[0019] FIG. 8A is a data plot showing plasma TLR4 levels detected in longitudinal samples obtained from a human subject.
[0020] FIG. 8B is a data plot showing a standard curve (y-axis: mean value; x-axis: concentration).
[0021] FIGS. 9A-9D show data plots TLR4 levels detected in longitudinal samples obtained from a human subject. FIG. 9A is a data plot showing serum TLR4 levels detected in longitudinal samples obtained from the human subject. FIG. 9B is a data plot showing plasma TLR4 levels detected in the last three longitudinal samples obtained from the human subject. FIG. 9C is a data plot showing plasma TLR4 levelsAttorney Docket Number 0184.0350-PCT (P18916-02)(raw data) detected in all longitudinal samples obtained from the human subject. FIG.9D is a data plot showing the fold change in plasma TLR4 levels detected in all longitudinal samples obtained from the human subject.DEFINITIONS
[0022] In order for the present disclosure to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms may be set forth throughout the specification. If a definition of a term set forth below is inconsistent with a definition in an application or patent that is incorporated by reference, the definition set forth in this application should be used to understand the meaning of the term.
[0023] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to “a method” includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
[0024] The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
[0025] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1 , 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
[0026] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. Further, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In describing and claiming the methods, reaction mixtures,Attorney Docket Number 0184.0350-PCT (P18916-02)devices, kits, and systems, the following terminology, and grammatical variants thereof, will be used in accordance with the definitions set forth below.
[0027] About: As used herein, “about” or “approximately” or “substantially” as applied to one or more values or elements of interest, refers to a value or element that is similar to a stated reference value or element. In certain embodiments, the term “about” or “approximately” or “substantially” refers to a range of values or elements that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value or element unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value or element). In some embodiments, the term “about” when used in reference to a measurement (e.g., "at least about 0.5 ng / mL"), this term allows for a variation of ±10% to account for standard deviations in ELISA assays or other detection methods.
[0028] Administer: As used herein, “administer” or “administering” a therapeutic agent (e.g., an immunological therapeutic agent) to a subject means to give, apply or bring the composition into contact with the subject. Administration can be accomplished by any of a number of routes, including, for example, topical, oral, subcutaneous, intramuscular, intraperitoneal, intravenous, intrathecal and intradermal.
[0029] Biological Sample As used herein, “biological sample” refers to any material obtained from a subject for the purpose of measurement, including whole blood, plasma, serum, and feces.
[0030] Circulating Toll-like receptor 4 (TLR4): As used herein, “circulating Toll-like receptor 4” or “TLR4” refers to a soluble or extracellular TLR4 protein detected in a biological sample obtained from a location other than the intestinal tissue itself. This primarily refers to TLR4 protein found in plasma, serum, whole blood, or stool.
[0031] Early-Stage NEC (Medical NEC): As used herein, “early-stage NEC” or medical NEC” refers to a stage of the disease where the pathology is manageable through medical protocols, such as cessation of feeds (NPO status), decompression, and administration of intravenous antibiotics. Clinically, medical NEC is characterized by peak levels of circulating TLR4, which are significantly higher than those observed in late-stage or surgical NEC.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0032] Initial Recovery Phase: As used herein, “initial recovery phase” refers to a period of clinical improvement following acute NEC treatment, often marked by the subject becoming "tolerating of feeds" and the completion of an antibiotic course.
[0033] Intestinal Necrosis: As used herein, “intestinal necrosis” refers to the death of cells within the intestinal epithelium caused by factors such as epithelial TLR4 activation, which leads to cell death via apoptosis, autophagy, or necroptosis.
[0034] Late-Stage NEC (Surgical NEC): As used herein, “late-stage NEC” or “surgical NEC” refers to a severe or advanced progression of NEC characterized by irreversible intestinal damage, such as intestinal necrosis, perforation, or the formation of abscesses, typically requiring surgical intervention. In this stage, circulating TLR4 levels have typically declined from their early peak but remain detectable.
[0035] NEC-Related Complication: As used herein, “NEC-related complication” refers to a secondary medical issue arising from the progression of NEC, such as an abdominal abscess or portal venous gas.
[0036] Necrotizing Enterocolitis (NEC): As used herein, “necrotizing enterocolitis” or “NEC” refers to a gastrointestinal disease prevalent in premature infants characterized by acute development of intestinal inflammation and necrosis. Clinical findings typically include abdominal distention, bloody stools, and systemic sepsis.
[0037] Premature Infant: As used herein, “premature infant” refers to a human subject bom before full gestational term. This includes infants born at approximately 34 weeks of gestation or earlier, who are at a 10-fold higher risk for NEC than full-term infants.
[0038] Reference Level or Predetermined Threshold: As used herein, “reference level” or “predetermined threshold” refers to a baseline value used for comparison to determine the presence or stage of NEC. This may be based on levels in healthy controls or mean levels in subjects known to have a specific stage of the disease.
[0039] Sample: As used herein, “sample” means anything capable of being analyzed by the methods, devices, and / or systems disclosed herein.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0040] SIGIRR Mutation: As used herein, “SIGIRR mutation” refers to a genetic alteration in the SIGIRR gene, such as a "stop mutation," that disrupts the normal inhibitory function of SIGIRR on the TLR4 pathway, thereby increasing the risk of severe NEC.
[0041] Significantly Elevated: As used herein, “significantly elevated” refers to a concentration of circulating TLR4 that is statistically higher than a control level, such as a 2-fold or greater increase over a non-NEC baseline.
[0042] Single immunoglobulin interleukin-1 -related receptor (SIGIRR): As used herein, “single immunoglobulin interleukin-1 -related receptor” or “SIGIRR” refers to a gene encoding a protein that serves as a critical inhibitor of the TLR4 signaling pathway.
[0043] Subject: As used herein, “subject” refers to an animal, such as a mammalian species (e.g., human, dog, cat) or avian (e.g., bird) species. More specifically, a subject can be a vertebrate, e.g., a mammal such as a mouse, a primate, a simian ora human. Animals include farm animals (e.g., production cattle, dairy cattle, poultry, horses, pigs, and the like), sport animals, and companion animals (e.g., pets or support animals). In certain embodiments, the subject is a human. In certain embodiments, the subject is a companion animal, including, but not limited to, a dog or a cat. A subject can be a healthy individual, an individual that has or is suspected of having a disease or a predisposition to the disease, or an individual that is in need of therapy or suspected of needing therapy. The terms “individual” or “patient” are intended to be interchangeable with “subject.”
[0044] System: As used herein, "system" in the context of analytical instrumentation refers a group of objects and / or devices that form a network for performing a desired objective.
[0045] Therapeutically Effective Amount. As used herein, the term "therapeutically effective amount" refers to an amount of a TLR4 inhibitor (e.g., a small molecule, peptide, or glycan) sufficient to achieve a statistically significant reduction in intestinal inflammation or mucosal injury when compared to an untreated control. In the neonatal population, this amount is characterized by a weight-based dosage (e.g., pg / kg to mg / kg per day) administered in a volume appropriate for the extremely limited fluid capacity of a premature infant’s stomach. The "effectiveness" of the amount isAttorney Docket Number 0184.0350-PCT (P18916-02)measured by its ability to prevent progression through, or induce regression from, the Bell Staging Criteria:• For Bell Stage I (Suspected NEC): A therapeutically effective amount is defined as a dose sufficient to resolve gastric residuals and abdominal distension within a specified timeframe (e.g., 24-48 hours) and prevent the radiographic emergence of pneumatosis intestinalis.• For Bell Stage II (Proven NEC): The amount is sufficient to halt the spread of pneumatosis intestinalis, normalize inflammatory biomarkers (e.g., C-reactive protein or fecal calprotectin), and prevent the transition to stage III.• For Bell Stage III (Advanced NEC): The amount is sufficient to stabilize systemic hemodynamics, reduce the necessity for surgical bowel resection, and minimize the risk of intestinal perforation.
[0046] TLR4-Targeted Therapy / TLR4 Inhibitor. As used herein, a “TLR4-targeted therapy” or “TLR4 inhibitor” refers to a therapeutic agent that binds to, blocks, or inhibits the activation of the TLR4 receptor. Examples include human milk oligosaccharides (e.g., 2'-fucosyllactose) and small-molecule inhibitors.
[0047] Treat. As used herein, the term “treat,” “treating” or “treatment” are each used interchangeably herein to describe reversing, alleviating, or inhibiting the progress of a disease and / or injury, or one or more symptoms of such disease, to which such term applies. Depending on the condition of the subject, the term also refers to preventing a disease, and includes preventing the onset of a disease, or preventing the symptoms associated with a disease (e.g., viral infection). A treatment may be either performed in an acute or chronic way. The term also refers to reducing the seventy of a disease or symptoms associated with such disease prior to affliction with the disease. Such prevention or reduction of the severity of a disease prior to affliction refers to administration of a treatment to a subject that is not at the time of administration afflicted with the disease. “Preventing” also refers to preventing the recurrence of a disease or of one or more symptoms associated with such disease.
[0048] Window for Medical Management: As used herein, “window for medical management” refers to a critical timeframe in early NEC where clinical intervention can prevent the progression to intestinal necrosis or the need for surgery.Attorney Docket Number 0184.0350-PCT (P18916-02)DETAILED DESCRIPTION
[0049] Reference will now be made in detail to example implementations. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention and it is to be understood that other embodiments may be utilized and that changes may be made without departing from the scope of the invention. The following description is, therefore, merely exemplary.
[0050] In some aspects, the present disclosure provides methods, kits, and systems that are useful in detecting necrotizing enterocolitis (NEC) in subjects (e.g., human subjects, especially premature infants). In some embodiments, these aspects are configured as companion diagnostic tools of use in, for example, identifying therapies most suitable for treating NEC in a given subject diagnosed with the disease. In some embodiments, the various aspects of the present disclosure are implemented in treating subjects diagnosed with NEC. These and other attributes will be apparent upon a complete review of the present disclosure, including the accompanying figures.
[0051] Necrotizing Enterocolitis (NEC) is a devastating inflammatory disease of the gastrointestinal tract, primarily affecting neonates. It is characterized by variable degrees of mucosal or transmural necrosis of the intestine. NEC represents one of the leading causes of morbidity and mortality in Neonatal Intensive Care Units (NICUs) globally. While the condition can occur in full-term infants, it disproportionately affects preterm infants — particularly those bom at a very low birth weight (VLBW, <1500g) or extremely low birth weight (ELBW, <1000g).
[0052] The exact pathogenesis of NEC is multifactorial, often described as a "perfect storm" of biological vulnerabilities. In premature infants, the condition typically arises from a combination of the following factors:• Intestinal Immaturity: The preterm gut possesses an underdeveloped mucosal barrier, impaired peristalsis, and suboptimal secretion of protective mucus and IgA. This structural fragility makes the intestinal wall highly susceptible to injury.• Microbiome Dysbiosis: Unlike the diverse microbial environment of a full-term infant, the preterm gut is often colonized by a narrow range of pathogenic bacteria (e.g., Proteobacteria). This dysbiosis triggers an exaggerated inflammatory response.Attorney Docket Number 0184.0350-PCT (P18916-02)• Abnormal Immune Response: The premature immune system often exhibits an over-expression of Toll-like receptor 4 (TLR4). In a mature gut, TLR4 regulates development, but in a preterm gut, its activation by bacteria can trigger a cascade of pro-inflammatory cytokines, leading to severe epithelial cell apoptosis and impaired tissue repair.• Ischemia-Reperfusion Injury: Fluctuations in blood flow to the mesenteric arteries — often caused by systemic hypotension or cardiac complications — can lead to localized hypoxia, further compromising the integrity of the intestinal lining.
[0053] The clinical onset of NEC is often sudden and can progress from mild feeding intolerance to systemic shock within hours. Clinical staging is typically categorized using Bell’s Staging Criteria:• Stage I (Suspected): Characterized by non-specific systemic signs (apnea, bradycardia), gastric residuals, and mild abdominal distension.• Stage II (Proven): Marked by persistent abdominal tenderness and the hallmark radiographic finding of pneumatosis intestinalis (gas within the bowel wall).• Stage III (Advanced): Progresses to intestinal perforation, pneumoperitoneum, septic shock, and multi-organ failure.
[0054] The incidence of NEC is inversely proportional to gestational age and birth weight. Approximately 7% to 10% of VLBW infants develop the disease. Mortality rates remain high, ranging from 20% to 30%, and can exceed 50% in cases requiring surgical intervention.
[0055] Survivors of NEC often face significant long-term sequelae, including:• Short Bowel Syndrome (SBS): Resulting from extensive surgical resection of necrotic tissue, leading to malabsorption and lifelong parenteral nutrition dependency.• Neurodevelopmental Impairment: There is a documented correlation between neonatal NEC and long-term cognitive and motor delays, likely due to the systemic inflammatory "hit" to the developing brain.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0056] Despite decades of research, the standard of care remains largely reactive (bowel rest, broad-spectrum antibiotics, and surgery). There is a critical unmet need for technologies and therapeutics focused on early diagnostic biomarkers, prophylactic interventions to stabilize the gut-vascular barrier, and targeted modulators of the neonatal innate immune response to prevent the catastrophic progression of the disease.
[0057] Some embodiments of the present disclosure involve detecting level of circulating Toll-like receptor 4 (TLR4) in samples obtained from subjects. TLR4 (also known as CD284) is a member of the Toll-like receptor family that functions as a transmembrane pattern recognition receptor (PRR). In humans, TLR4 is encoded by the TLR4 gene (NCBI Gene ID: 7099). Circulating TLR4 protein is found within the systemic circulation of a subject (e.g., a human patient). This includes, but is not limited to, cell-surface TLR4 expressed on the plasma membrane of circulating peripheral blood mononuclear cells (PBMCs), such as monocytes, neutrophils, and dendritic cells, and soluble TLR4 (sTLR4) fragments or the full extracellular domain of TLR4 that have been shed or secreted into the plasma, serum, or other extracellular fluids.
[0058] The full-length human TLR4 protein typically consists of approximately 839 amino acids (e.g., UniProt P33527) and is characterized by three distinct domains:1. Extracellular Domain (ECD): A large horseshoe-shaped domain (approx, residues 24-631) containing multiple leucine-rich repeats (LRRs). The ECD is responsible for the recognition of pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), and damage-associated molecular patterns (DAMPS), such as HMGB1.2. Transmembrane Domain: A single-pass helical region (approx, residues 632-652).3. Intracellular Toll / lnterleukin-1 Receptor (TIR) Domain: A cytoplasmic signaling domain (approx, residues 653-839) that initiates downstream cascades (e.g., MyD88-dependent or TRIF-dependent pathways) upon ligand-induced dimerization.
[0059] In one embodiment, the circulating TLR4 comprises the receptor expressed on the surface of CD14+ monocytes. In healthy subjects, a baseline percentage of monocytes (e.g., ~30-45%) may express TLR4. In subjects having anAttorney Docket Number 0184.0350-PCT (P18916-02)inflammatory or infectious condition (e.g., sepsis, acute coronary syndrome, or autoimmune disease), the expression level of TLR4 per cell (Mean Fluorescence Intensity, MFI) or the frequency of TLR4-positive (TLR4+) cells may be significantly elevated (e.g., >70% of monocytes).
[0060] In another embodiment, the circulating TLR4 is a soluble isoform (sTLR4) found in the serum or plasma. Soluble TLR4 may result from the proteolytic cleavage (shedding) of the extracellular domain from the cell surface or via alternative splicing of the TLR4 mRNA. sTLR4 levels in the circulation can serve as a biomarker for the activation state of the innate immune system. High levels of sTLR4 (e.g., exceeding a threshold of 10 ng / mL, 50 ng / mL, or 100 ng / mL, depending on the assay) are associated with poor prognosis in chronic inflammatory diseases or acute exacerbations.
[0061] In some embodiments, flow cytometry is used for detecting cell-surface TLR4, while an Enzyme-Linked Immunosorbent Assay (ELISA) is used for detecting soluble TLR4. Any other suitable detection technique is also optionally utilized.
[0062] Circulating TLR4 rarely acts in isolation. For the purposes of this disclosure, a description of TLR4 may include its association with circulating accessory proteins:• MD-2 (LY96): A soluble or membrane-associated protein that forms a stable heterodimer with the TLR4 ECD to facilitate LPS binding.• CD14: A glycosylphosphatidylinositol (GPI)-anchored or soluble protein (sCD14) that enhances the sensitivity of TLR4 to low concentrations of ligands.
[0063] To further illustrate, the detection or quantification of circulating TLR4 in a subject can be utilized for:• Diagnosis / Prognosis: Predicting the severity of NEC.• Patient Stratification: Identifying "high-responders" to TLR4-targeted therapies (e.g., TLR4 antagonists or monoclonal antibodies).• Monitoring: Assessing the efficacy of an NEC treatment by measuring changes in TLR4 expression on circulating leukocytes over time.
[0064] In some embodiments, the methods and other aspects of the presentAttorney Docket Number 0184.0350-PCT (P18916-02)disclosure further comprise detecting a mutation in a single immunoglobulin interleukin-1 -related receptor (SIGIRR) gene of the subject. The human SIGIRR gene (NCBI Gene ID: 59307) (also known as IL-1 R8 orTIR8) is a member of the interleukin-1 receptor (IL-1 R) superfamily. It is localized on Chromosome 11 (11p15.5) (Ensembl, 2024). The gene spans approximately 11.7 kilobases (kb) of genomic DNA on the reverse strand (UCSC Genome Browser, 2024). In humans, the gene typically consists of 10 exons. This distinguishes it from the murine ortholog (Sigirr), which contains 9 exons (Wikipedia, 2024). The primary transcript (e.g., RefSeq NM_021805.3) encodes a protein of approximately 410 amino acids (UniProt Q6IA17).
[0065] The SIGIRR protein is a Type I transmembrane receptor with a unique structural configuration that differentiates it from other IL-1 R family members (which typically possess three extracellular Ig domains). The ECD contains a single immunoglobulin (Ig)-like C2-type domain (approximately residues 1-154). This singledomain structure is the defining feature of the "Single Ig" nomenclature. It serves as the primary interface for ligand binding, specifically with Interleukin-37 (IL-37), which is currently the only confirmed extracellular cytokine ligand for SIGIRR. A single-pass hydrophobic region (a transmembrane helix) anchors the receptor in the plasma membrane. The SIGIRR protein includes a conserved Toll / lnterleukin-1 Receptor (TIR) domain (approximately residues 164-300). Unlike other TLRs / IL-1 Rs, SIGIRR possesses an unusually long 95-amino acid C-terminal extension. This tail is critical for its inhibitory function, as it physically interferes with the assembly of signaling complexes.
[0066] In the context of the present disclosure, SIGIRR is characterized as a negative regulator of the Toll-like receptor (TLR) and IL-1 R signaling pathways. The SIGIRR protein sequesters key adapter molecules, including MyD88, IRAKI, and TRAF6, preventing them from forming the "myddosome" complex required for NF-KB activation. The SIGIRR protein specifically attenuates signaling from TLR4, TLR5, TLR7, and TLR9. In addition, while constitutively expressed to maintain homeostasis, The SIGIRR protein’s inhibitory activity is enhanced upon binding with the antiinflammatory cytokine IL-37.
[0067] Human SIGIRR undergoes alternative splicing. For example, a dominant-negative splice variant lacking exon 8 has been identified in human colorectal tumors. This variant is unable to inhibit TLR signaling, thereby promoting aAttorney Docket Number 0184.0350-PCT (P18916-02)pro-tumorigenic inflammatory microenvironment (NCBI Gene ID: 59307, 2024). SIGIRR is highly expressed in epithelial tissues (kidney, lung, gut) and lymphoid organs (spleen), where it serves to prevent "overshooting" immune responses that could lead to tissue.
[0068] In some embodiments, for example, the methods and other aspects of the present disclosure comprise detecting p.Y168X (c.504C>G), which is a stop mutation that results in the premature termination of the SIGIRR protein. This mutation truncates the protein before the critical TIR (Toll / lnterleukin-1 Receptor) domain, rendering it incapable of sequestering adapter molecules like MyD88 or TRAF6. This variant is strongly associated with Necrotizing Enterocolitis (NEC) in premature infants.
[0069] II. Exemplary Embodiments
[0070] To illustrate, FIG. 1A is a flowchart that shows an exemplary method of detecting or diagnosing necrotizing enterocolitis (NEC) in a subject (e.g., a premature infant). As shown, method 100 includes measuring a level of circulating Toll-like receptor 4 (TLR4) in a biological sample obtained from the subject (step 102). In some embodiments, the biological sample is selected from, for example, whole blood, serum, plasma, and feces, among other sample types. Method 100 also includes comparing the measured level to a reference level in which a level above the reference level is indicative of NEC (step 104). In some embodiments, the measured level of TLR4 is at least about 0.5 ng / mL, or at least about 1 ng / mL, or at least about 5 ng / mL.
[0071] In some embodiments, method 100 includes detecting an early-stage NEC in the subject when the level of circulating TLR4 is significantly elevated compared to a level associated with late-stage NEC. In some embodiments, method 100 includes monitoring the subject for NEC-related complications or recurrence in which a rise in circulating TLR4 levels follows an initial recovery phase. In some embodiments, method 100 further includes detecting a mutation in a single immunoglobulin interleukin-1 -related receptor (SIGIRR) gene of the subject in which the presence of a SIGIRR mutation and an elevated level of TLR4 together indicate a high risk of severe NEC.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0072] To illustrate, FIG. 1B is a flowchart that shows an exemplary companion diagnostic method for selecting a subject with necrotizing enterocolitis (NEC) for a specific therapeutic intervention. As shown, method 106 includes measuring a level of circulating Toll-like receptor 4 (TLR4) in a sample from the subject (step 108). Method 106 also includes administering a TLR4-targeted therapy or an NEC-specific treatment to the subject if the level of TLR4 is above a predetermined threshold (step 110). In some embodiments, method 106 the NEC-specific treatment comprises one or more of: administration of antibiotics, cessation of formula feeds, administration of breast milk or human milk oligosaccharides, and / or surgical intervention. In some embodiments, the level of TLR4 is measured to determine the timing of the intervention in which an elevated level identifies a window for medical management prior to the development of intestinal necrosis.
[0073] To further illustrate, FIG. 1C is a flowchart that shows an exemplary method of treating necrotizing enterocolitis (NEC) in a subject. As shown, method 112 includes obtaining a biological sample from a subject suspected of having NEC (step 114). Method 112 also includes detecting a level of circulating Toll-like receptor 4 (TLR4) in the sample (step 116). In addition, method 112 also includes administering an NEC therapy to the subject if the level of TLR4 is at least 0.5 ng / mL to thereby treating the NEC (step 118). In some embodiments, the NEC therapy comprises a TLR4 inhibitor (also referred to as a "TLR4 antagonist"). In one embodiment, the TLR4 inhibitor is a small molecule compound, a carbohydrate mimetic, or a biological agent that prevents the activation of the TLR4-MD2 complex by its primary ligand, lipopolysaccharide (LPS).
[0074] Some more specific exemplary embodiments of TLR4 Inhibitors, include:• Small Molecule Inhibitors: Compounds such as TAK-242 (Resatorvid) and its derivatives, which bind to the intracellular domain of TLR4 (specifically Cys747) to disrupt the recruitment of adapter proteins like MyD88 and TRIF.• Lipid A Mimetics / Antagonists: Synthetic analogs of the lipid A portion of LPS, such as Eritoran (E5564), which competitively bind to the MD2 pocket, preventing the formation of the active TLR4 / MD2 / LPS signaling dimer.Attorney Docket Number 0184.0350-PCT (P18916-02)• Novel Glial-Mediated Modulators: Agents that stimulate the release of Brain-Derived Neurotrophic Factor (BDNF) from enteric glia, thereby indirectly restraining epithelial TLR4 signaling (e.g., the small molecule lead compound J11).• Oligosaccharide-Based Inhibitors: Human Milk Oligosaccharides (HMOs) or synthetic glycans that mimic the TLR4-neutralizing properties found in human breast milk.
[0075] In the context of the present disclosure, the TLR4 inhibitor functions through several distinct therapeutic pathways localized to the premature intestinal environment:• Suppression of Pro-inflammatory Signaling: By blocking the MyD88-dependent pathway, the inhibitor prevents the translocation of NF-KB to the nucleus, thereby reducing the production of deleterious cytokines including IL-6, IL-1 , and TNF-a.• Restoration of Enterocyte Homeostasis: TLR4 over-activation in premature infants inhibits enterocyte proliferation and migration. The inhibitor reverses this by stabilizing 0-catenin and reducing RhoA / FAK activity, allowing for the repair of the intestinal mucosal barrier.• Preservation of Intestinal Perfusion: The inhibitor prevents TLR4-mediated downregulation of endothelial nitric oxide synthase (eNOS). By maintaining eNOS activity, the inhibitor ensures adequate microcirculatory blood flow to the ileum, preventing ischemic necrosis.• Protection of Enteric Glia: The inhibitor mitigates the loss of enteric glia, which are otherwise susceptible to TLR4-induced apoptosis, thereby preserving the autonomic regulation of the gut.
[0076] Given the specific physiological constraints of premature neonates (e.g., immature renal / hepatic function and the presence of enteral feeding tubes), the invention provides specialized formulations:• Enteral Formulations: The TLR4 inhibitor may be formulated as an oral solution, a powder for reconstitution, or an additive to breast milk or infant formula. This allows for direct local delivery to the intestinal mucosa — the primary site of NEC pathology.Attorney Docket Number 0184.0350-PCT (P18916-02)• Parenteral Formulations: For infants in advanced stages of NEC (Bell Stage II or III) who are on "bowel rest," the invention includes sterile intravenous or intraperitoneal solutions.• Targeted Delivery: In certain embodiments, the inhibitor is encapsulated in nanoparticles or liposomes targeted to the intestinal epithelium or vascular endothelium to minimize systemic off-target effects.
[0077] The present disclosure provides a method for treating a neonatal patient at risk of, or diagnosed with, NEC by administering a therapeutically effective amount of the TLR4 inhibitor. Some embodiments include administering an inhibitor to Very Low Birth Weight (VLBW) infants during the first 14 days of life to prevent the onset of inflammatory cascades triggered by initial bacterial colonization, for example, as a prophylactic use. Some embodiments include administering an inhibitor upon the first clinical signs of feeding intolerance or the radiographic appearance of pneumatosis intestinalis to halt the progression to transmural necrosis or perforation, for example, as an acute treatment.
[0078] In some embodiments, there is a preference for local (enteral) delivery over systemic (intravenous) administration. This approach is rooted in the unique pathophysiology of NEC, where the primary site of TLR4 over-activation is the apical surface of the intestinal epithelium. By administering the TLR4 inhibitor enterally (via orogastric or nasogastric tube), the active agent is delivered directly to the site of initial bacterial colonization and inflammation. This maximizes the local concentration at the enterocyte level while maintaining a low systemic profile. Unlike adult Gl tracts, the premature gut has increased permeability. Enteral delivery allows the inhibitor to penetrate the compromised mucosal barrier effectively, targeting the TLR4 receptors on both the epithelial and sub-epithelial layers (including the enteric nervous system). The use of enteral TLR4 inhibitors for NEC is distinguished from, for example, systemic TLR4 antagonist delivery protocols attempted in clinical trials involving adult sepsis patients.
[0079] In some embodiments, the present disclosure provides various kits of use in performing the methods disclosed herein. In some embodiments, for example, a kit is provided for the diagnosis of necrotizing enterocolitis (NEC) in a premature infant. The kit includes a reagent for specifically detecting Toll-like receptor 4 (TLR4)Attorney Docket Number 0184.0350-PCT (P18916-02)in a plasma or stool sample. The kit also includes instructions for using the reagent to detect NEC or a complication of NEC in the subject based on a measured TLR4 level.
[0080] In some embodiments, the present disclosure also provides various systems and related computer readable media of use in implementing the methods disclosed herein. To illustrate, FIG. 2 is a schematic diagram of a hardware computer system 200 suitable for implementing various embodiments. For example, FIG. 2 illustrates various hardware, software, and other resources that can be used in implementations of any of methods disclosed herein, including methods 100, 106, and 112. System 200 includes controller terminal 202 and computer 201. Terminal 202 and computer 201 may be communicatively coupled by way of one or more networks 204, e.g., the internet. In some embodiments, controller terminal 202 and computer 201 together comprise processing and computation modules of system 200.
[0081] Computer 201 may be implemented as any of a desktop computer, a laptop computer, can be incorporated in one or more servers, clusters, or other computers or hardware resources, or can be implemented using cloud-based resources. Computer 201 includes volatile memory 214 and persistent memory 212, the latter of which can store computer-readable instructions, that, when executed by electronic processor 210, configure computer 201 to perform any of the methods disclosed herein, including method 200. Computer 201 further includes network interface 208, which communicatively couples computer 201 to terminal 202 and to assay device 203, which is configured to measure Toll-like receptor 4 (TLR4) in a biological sample via network 304. Other configurations of system 200, associated network connections, and other hardware, software, and service resources are possible. In some embodiments, assay device 203 is implemented as a stand-alone system for measuring TLR4 in a biological sample using the methods disclosed herein. In some embodiments, assay device 203 comprises a flow cytometer or an ELISA assay device.
[0082] Certain embodiments can be performed using a computer program or set of programs. The computer programs can exist in a variety of forms both active and inactive. For example, the computer programs can exist as software program(s) comprised of program instructions in source code, object code, executable code or other formats; firmware program(s), or hardware description language (HDL) files. Any of the above can be embodied on a transitory or non-transitory computer readableAttorney Docket Number 0184.0350-PCT (P18916-02)medium, which include storage devices and signals, in compressed or uncompressed form. Exemplary computer readable storage devices include conventional computer system RAM (random access memory), ROM (read-only memory), EPROM (erasable, programmable ROM), EEPROM (electrically erasable, programmable ROM), and magnetic or optical disks or tapes.
[0083] III. EXAMPLES
[0084] EXAMPLE 1 : A non-invasive biomarker assay for the diagnosis of necrotizing enterocolitis in premature infants
[0085] Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease in premature infants. There are no accurate NEC diagnostic tests available for clinical use. Existing strategies are based on non-specific cytokine detection that are not linked to the pathogenesis of the disease in any way.
[0086] The development of NEC requires TLR4 signaling in the intestinal epithelium in mice and humans
[0087] The inventors have advanced a unifying hypothesis to explain the pathogenesis of NEC which has now been supported by experimental findings from labs around the world. This hypothesis is based on the discovery that activation of the lipopolysaccharide (LPS) receptor Toll-like Receptor 4 (TLR4) on the intestinal epithelium plays an important role in the development of NEC. As proof, intestinal-specific TLR4-KO mice were protected from NEC (FIGS. 3A-3C), whereas in humans, stop mutations in the SIGIRR (Single immunoglobulin interleukin-1 -related receptor) gene - which is a critical inhibitor of TLR4 pathway- were found in a majority of infants with severe NEC. Breast milk - long known to protect against NEC - is enriched in TLR4 inhibitors, providing further evidence for the role of TLR4 in NEC induction. In terms of tying TLR4 to disease development, the inventors have shown that intestinal epithelial TLR4 activation leads to intestinal epithelial cell death by apoptosis, autophagy, and necroptosis. TLR4 activation also impairs intestinal mucosal restitution via a reduction in both enterocyte proliferation and migration, which together lead to bacterial translocation across the intestinal mucosa. Mice lacking Tlr4 on the intestinal epithelium are protected from NEC as revealed by improved gross and histopathology (FIGS. 3D-3F), a reduction in the extent of oxidative injury as revealed by the reactive oxygen species (ROS) marker DHE (FIGS. 3G-3I), reduced TnfaAttorney Docket Number 0184.0350-PCT (P18916-02)expression (FIG. 3J) and lower NEC injury score (FIG. 3K). The inventors have now further determined that levels of TLR4 rise in blood and stool before the onset of clinical NEC in mice and humans, providing a novel diagnostic test for this disease.
[0088] TLR4 detection in the serum and stool for the diagnosis of NEC
[0089] Validation in models of LPS injection: In order to test the ability of circulating TLR4 levels to detect NEC in mice and humans, we first performed studies in wild-type and TLR4 KO mice that were injected with either the TLR4 ligand lipopolysaccharide (LPS) (i.p., 10 mg / kg) or normal saline (i.p., 5 ml / kg) injections at 6 weeks of age. After six hours, mice were euthanized. Plasma was obtained from centrifugation of whole blood at 1000 RCF for 10 minutes in an EDTA-coated vial. Plasma TLR4 concentration was analyzed with a commercially available ELISA kit for mouse TLR4.
[0090] Validation in experimental NEC in mice: We then measured TLR4 in the blood and stool of neonatal mice who developed experimental NEC within our well-established disease model. Briefly, C57 BL / 6 neonatal mice were separated from dams at postnatal day 7 and received oral gavage 5 times daily of canine milk replacer (40 ul / g body weight) containing enteric bacteria from the stool of a human infant with NEC. Experimental mice were subjected to twice daily hypoxia (5% FiO2) for 10 minutes to recapitulate the intermittent apnea and hypoxemia seen in preterm human infants. After a range of time course durations (6 hours-3 days) of NEC treatment, mice were euthanized and plasma was obtained as above. Stool was isolated from the full length of resected colon, manually homogenized in ice cold protease inhibitor buffer, and centrifuged at 12000 RCF for 10 minutes. After measurement of total protein by BCA assay, the protein supernatant was assayed for TLR4 using the ELISA kit described above.
[0091] Results
[0092] 1. LPS injection led to a sharp rise in plasma TLR4 levels in wild-type mice, while that of TLR4- / - mice was unchanged by LPS treatment, confirming assay specificity (FIG. 4).
[0093] 2. Importantly, mice induced to develop NEC revealed a robust and early increase in plasma TLR4 (FIG. 5) early in the course of the disease.
[0094] 3. We next sought to test for the levels of TLR4 in human bloodAttorney Docket Number 0184.0350-PCT (P18916-02)samples with and without NEC. To do so, blood was obtained from discarded samples from NEC patients who were either early NEC patients (medical NEC) or late / severe NEC (surgical NEC). As shown in FIG. 7, patients with early NEC had much higher plasma TLR levels than NEC patients with more severe NEC (FIG. 6). The diagnosis of NEC in late stages is quite straight forward, but it is the early NEC where a diagnostic test is so important. In these studies, samples were obtained under JHU IRB.
[0095] 4. Lastly, stool TLR4 from experimental mouse NEC showed a robust and early increase in NEC treatment (FIG. 7).
[0096] EXAMPLE 2: Exemplary human patient 160
[0097] A total of 5 samples were obtained from patient 160 across 5 days (all samples were ‘discarded’ plasma and were stored by the lab at -80 prior to collection and stored at -80 in the lab prior to ELISA). Blood is stored for 72 hours prior to collection by lab team as ‘discarded samples’.
[0098] Human patient 160 was a 6-day old male born 34w2d. The pregnancy was complicated by gestational diabetes, pre-eclampsia, and delivery was complicated by shoulder dystocia. The patient was fed immediately, tolerated breast milk and formula. The patient made it to goal feeds, then developed bloody bowel movements and pneumatosis on x-ray as well as portal venous gas on US on 3 / 9 / 26. The patient was initially treated with NPO, IV antibiotics (abx), and decompression with serial x-rays. The patient completed a course of antibiotics for medical NEC (7 days). The patient slowly advanced feeds upon completion of abx and was discharged on 4 / 1 / 26, tolerating feeds.
[0099] Longitudinal detected TLR4 levels (ng / mL) for patient 160 are shown in FIG. 8A, where 0 corresponds to day 0 or day of diagnosis of NEC and 1 corresponds to day 1 of NEC (time of first sample).
[0100] Protocol: Used Sigma Aldrich Human TLR-4 ELISA Kit (RAB1088-1KT) minimum detection of 0.4 ng / mL. Kit recommended a dilution factor for plasma of 2-fold dilution in 1X Assay Diluent Buffer. 1X Assay Diluent Buffer was prepared fresh day of the assay.
[0101] All dilutions and standards were prepared fresh the day of the assay according to the protocol. FIG. 8B is a data plot showing the 4 parameter log fitAttorney Docket Number 0184.0350-PCT (P18916-02)standard curve (y-axis: mean value; x-axis: concentration). The curve fit standard curve was calculated using the 4-parameter logistic (curve fit results are presented in Table 1):Table 1Parameter Estimated Value Standard Error Confidence Interval StandardA 0.076 0.019 [0.022, 0.129] R2= 1.000EC50 = 25.24 B 0.842 0.046 [0.713, 0.971] C 25.24 3.060 [16.74, 33.74] D 2.911 0.128 [2.557, 3.265]
[0102] 1. Bring all reagents and samples to room temperature (18-25 °C) before use. It is recommended that all standards and samples be run at least in duplicate.
[0103] 2. Label removable 8-well strips as appropriate for your experiment.
[0104] 3. Add 100 pL of each standard (see Reagent Preparation step 4) and sample into appropriate wells. Cover wells and incubate for 2.5 hours at room temperature with gentle shaking.
[0105] 4. Discard the solution and wash 4 times with 1 X Wash Solution. Wash by filling each well with Wash Buffer (300 pL) using a multi-channel Pipette or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
[0106] 5. Add 100 pL of 1X prepared biotinylated antibody (Reagent Preparation step 6) to each well. Incubate for 1 hour at room temperature with gentle shaking.
[0107] 6. Discard the solution. Repeat the wash as in step 4.
[0108] 7. Add 100 pL of prepared Streptavidin solution (see Reagent Preparation step 7) to each well. Incubate for 45 minutes at room temperature with gentle shaking.
[0109] 8. Discard the solution. Repeat the wash as in step 4.Attorney Docket Number 0184.0350-PCT (P18916-02)
[0110] 9. Add 100 pL of TMB One-Step Substrate Reagent to each well. Incubate for 30 minutes at room temperature in the dark with gentle shaking.
[0111] 10. Add 50 pL of Stop Solution to each well. Read at 450 nm immediately.Table 2: Raw Data - Corrected Plasma Result Based on 2-fold Dilution Sample Well Values Result Mean Result Std.Dev. CV% Corrected 1 A3 0.155 0.374 0.353 0.029 8.197 0.706 A4 0.148 0.3332 B3 0.134 0.257 0.404 0.209 51.625 0.808 B4 0.185 0.5513 C3 0.129 0.229 0.282 0.075 26.669 0.564 C4 0.148 0.3354 D3 0.146 0.324 0.342 0.026 7.469 0.684 D4 0.153 0.365 E3 0.145 0.319 0.319 1.863 113.87 0.638E4* 0.476* 2.953**Value removed due to being major outlier.
[0112] EXAMPLE 3: Exemplary human patient 161
[0113] FIG. 9A is a data plot showing serum TLR4 levels detected in longitudinal samples obtained from a human subject (human patient 161). This child was diagnosed with NEC at an outside hospital and was transferred here where she had two operations and seemed to improve. Then on day 10 became quite ill and was found to have an abdominal abscess. It appears that the serum TLR4 rises before the diagnosis of the NEC-related abscess and may be an earlier marker of abscess diagnosis. Note, that the levels of TLR4 started to rise in the serum before the child had the development of an abscess. This is very exciting as it suggests that serum TLR4 may not only be diagnostic of NEC but also may help identify complications of NEC (i.e., abscess formation).
[0114] FIG. 9B is a data plot showing plasma TLR4 levels detected in the last three longitudinal samples obtained from the human subject. FIG. 9C is a data plot showing plasma TLR4 levels (raw data) detected in all longitudinal samples obtained from the human subject. FIG. 9D is a data plot showing the fold change in plasma TLR4 levels detected in all longitudinal samples obtained from the human subject. After the subject’s sickness improved, the TLR4 levels dropped. This shows that TLR4Attorney Docket Number 0184.0350-PCT (P18916-02)levels reveal the clinical course and are an early marker of resolution of NEC. This further illustrates that methods and related aspects of the present disclosure can be used to guide therapy, specifically answering the question as to when therapy should be stopped, among other uses.
[0115] Some further aspects are defined in the following clauses:
[0116] Clause 1 : A method of detecting or diagnosing necrotizing enterocolitis (NEC) in a subject, the method comprising: measuring a level of circulating Toll-like receptor 4 (TLR4) in a biological sample obtained from the subject; and comparing the measured level to a reference level, wherein a level above the reference level is indicative of NEC.
[0117] Clause 2: The method of Clause 1 , wherein the subject is a premature infant.
[0118] Clause 3: The method of Clause 1 or Clause 2, wherein the biological sample is selected from the group consisting of: whole blood, serum, plasma, and feces.
[0119] Clause 4: The method of any one of the preceding Clauses 1-3, wherein the measured level of TLR4 is at least about 0.5 ng / mL, or at least about 1 ng / mL, or at least about 5 ng / mL.
[0120] Clause 5: The method of any one of the preceding Clauses 1-4, comprising detecting an early-stage NEC in the subject when the level of circulating TLR4 is significantly elevated compared to a level associated with late-stage NEC.
[0121] Clause 6: The method of any one of the preceding Clauses 1-5, comprising monitoring the subject for NEC-related complications or recurrence, wherein a rise in circulating TLR4 levels follows an initial recovery phase.
[0122] Clause 7 : The method of any one of the preceding Clauses 1 -6, further comprising: detecting a mutation in a single immunoglobulin interleukin-1 -related receptor (SIGIRR) gene of the subject; wherein the presence of a SIGIRR mutation and an elevated level of TLR4 together indicate a high risk of severe NEC.
[0123] Clause 8: A method for selecting a subject with necrotizing enterocolitis (NEC) for a specific therapeutic intervention, the method comprising: measuring a level of circulating Toll-like receptor 4 (TLR4) in a sample from the subject; andAttorney Docket Number 0184.0350-PCT (P18916-02)administering a TLR4-targeted therapy or an NEC-specific treatment to the subject if the level of TLR4 is above a predetermined threshold.
[0124] Clause 9: The method of Clause 8, wherein the NEC-specific treatment comprises one or more of: administration of antibiotics; cessation of formula feeds; administration of breast milk or human milk oligosaccharides; or surgical intervention.
[0125] Clause 10: The method of Clause 8 or Clause 9, wherein the level of TLR4 is measured to determine the timing of the intervention, wherein an elevated level identifies a window for medical management prior to the development of intestinal necrosis.
[0126] Clause 11: A method of treating necrotizing enterocolitis (NEC) in a subject, the method comprising: obtaining a biological sample from a subject suspected of having NEC; detecting a level of circulating Toll-like receptor 4 (TLR4) in the sample; and administering an NEC therapy to the subject if the level of TLR4 is at least 0.5 ng / mL, thereby treating the NEC.
[0127] Clause 12: The method of Clause 11, wherein the NEC therapy comprises a TLR4 inhibitor.
[0128] Clause 13: A kit for the diagnosis of necrotizing enterocolitis (NEC) in a premature infant, the kit comprising: a reagent for specifically detecting Toll-like receptor 4 (TLR4) in a plasma or stool sample; and instructions for using the reagent to detect NEC or a complication of NEC in the subject based on a measured TLR4 level.
[0129] Clause 14: A system for detecting necrotizing enterocolitis (NEC) comprising: an assay device configured to measure Toll-like receptor 4 (TLR4) in a biological sample; and a processor and memory containing instructions to compare the measured TLR4 level to a reference range and output a diagnostic result indicating the presence or stage of NEC.
[0130] Although this disclosure contains many specific embodiment details, these should not be construed as limitations on the scope of the subject matter or on the scope of what may be claimed, but rather as descriptions of features that may be specific to particular embodiments. Certain features that are described in this disclosure in the context of separate embodiments can also be implemented, in combination, in a single embodiment. Conversely, various features that are describedAttorney Docket Number 0184.0350-PCT (P18916-02)in the context of a single embodiment can also be implemented in multiple embodiments, separately, or in any suitable sub-combination. Moreover, although previously described features may be described as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can, in some cases, be excised from the combination, and the claimed combination may be directed to a sub-combination or variation of a sub-combination.
[0131] Particular embodiments of the subject matter have been described. Other embodiments, alterations, and permutations of the described embodiments are within the scope of the following claims as will be apparent to those skilled in the art. While operations are depicted in the drawings or claims in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed (some operations may be considered optional), to achieve desirable results.
[0132] Accordingly, the previously described example embodiments do not define or constrain this disclosure. Other changes, substitutions, and alterations are also possible without departing from the spirit and scope of this disclosure.
Claims
1. Attorney Docket Number 0184.0350-PCT (P18916-02)WHAT IS CLAIMED IS:
1. A method of detecting or diagnosing necrotizing enterocolitis (NEC) in a subject, the method comprising:measuring a level of circulating Toll-like receptor 4 (TLR4) in a biological sample obtained from the subject; andcomparing the measured level to a reference level, wherein a level above the reference level is indicative of NEC.
2. The method of claim 1 , wherein the subject is a premature infant.
3. The method of claim 1 , wherein the biological sample is selected from the group consisting of: whole blood, serum, plasma, and feces.
4. The method of claim 1 , wherein the measured level of TLR4 is at least about 0.5 ng / mL, or at least about 1 ng / mL, or at least about 5 ng / mL.
5. The method of claim 1 , comprising detecting an early-stage NEC in the subject when the level of circulating TLR4 is significantly elevated compared to a level associated with late-stage NEC.
6. The method of claim 1 , comprising monitoring the subject for NEC-related complications or recurrence, wherein a rise in circulating TLR4 levels follows an initial recovery phase.
7. The method of claim 1 , further comprising:detecting a mutation in a single immunoglobulin interleukin-1 -related receptor (SIGIRR) gene of the subject;wherein the presence of a SIGIRR mutation and an elevated level of TLR4 together indicate a high risk of severe NEC.
8. A method for selecting a subject with necrotizing enterocolitis (NEC) for a specific therapeutic intervention, the method comprising:measuring a level of circulating Toll-like receptor 4 (TLR4) in a sample from the subject; andadministering a TLR4-targeted therapy or an NEC-specific treatment to the subject if the level of TLR4 is above a predetermined threshold.
9. The method of claim 8, wherein the NEC-specific treatment comprises one or more of:administration of antibiotics;cessation of formula feeds;Attorney Docket Number 0184.0350-PCT (P18916-02)administration of breast milk or human milk oligosaccharides; or surgical intervention.
10. The method of claim 8, wherein the level of TLR4 is measured to determine the timing of the intervention, wherein an elevated level identifies a window for medical management prior to the development of intestinal necrosis.
11. A method of treating necrotizing enterocolitis (NEC) in a subject, the method comprising:obtaining a biological sample from a subject suspected of having NEC; detecting a level of circulating Toll-like receptor 4 (TLR4) in the sample; andadministering an NEC therapy to the subject if the level of TLR4 is at least 0.5 ng / mL, thereby treating the NEC.
12. The method of claim 11 , wherein the NEC therapy comprises a TLR4 inhibitor.
13. A kit for the diagnosis of necrotizing enterocolitis (NEC) in a premature infant, the kit comprising:a reagent for specifically detecting Toll-like receptor 4 (TLR4) in a plasma or stool sample; andinstructions for using the reagent to detect NEC or a complication of NEC in the subject based on a measured TLR4 level.
14. A system for detecting necrotizing enterocolitis (NEC) comprising:an assay device configured to measure Toll-like receptor 4 (TLR4) in a biological sample; anda processor and memory containing instructions to compare the measured TLR4 level to a reference range and output a diagnostic result indicating the presence or stage of NEC.
